Although cervical cancer is proven to be a preventable and treatable disease, in the year 2020, more than 500,000 women worldwide were suffering from it, and among which, approximately 342,000 died from it. A fast and accurate screening plan is critical for the prevention and early detection and is crucial for the elimination of cervical cancer.

The new guideline issued by WHO recommends HPV DNA testing as the preferred method, rather than the widely used visual inspection with acetic acid (VIA) or cytology (also often referred to as "Pap smear").

The guideline emphasizes that HPV DNA testing can detect high-risk types of HPV (rhHPV), which lead to almost all cases of cervical cancers. Unlike methods that rely on visual inspection that operates manually, HPV DNA testing is an objective diagnosis with an auto-analyzer that has comparably higher accuracy, especially among people with early and mid-stage cervical squamous cell lesions.

Key to curing cervical cancer, regular HPV screening will greatly reduce the chance of the infection. Bioperfectus Human Papillomavirus Real-Time PCR Kit is able to detect 96 samples in 100 minutes with the ability to respectively report HPV-16 and HPV-18 as primary evidence for cervical cancer screening. Bioperfectus Human Papillomavirus Genotyping Real-Time PCR Kit is designed to precisely detect 21 genotypes of HPV for further triage and treatment with reliable clinical performance.

Please visit our website: www.bioperfectus.com  to learn more or request information using the button provided below.